The role of microRNAs in stemness of cancer stem cells

Seyed Mohammad Ali Hosseini Rad,1,2 Mahsa Shanaki Bavarsad,3 Ehsan Arefian,1,4 Kaveh Jaseb,3 Mohammad Shahjahani,2 Najmaldin Saki1,3

1Department of Molecular Biology and Genetic Engineering, Stem Cell Technology Research Center, Tehran; 2Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran; 3Health Research Center, Research Institute of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz; 4Department of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran

Abstract

Cancer is one of the most important diseases of humans, for which no cure has been found so far. Understanding the causes of cancer can pave the way for its treatment. Alteration in genetic elements such as oncogenes and tumor suppressor genes results in cancer. The most recent theory for the origin of cancer has been provided by cancer stem cells (CSCs). Tumor-initiating cells (T-ICs) or CSCs are a small population isolated from tumors and hematologic malignancies. Since CSCs are similar to embryonic stem cells (ESCs) in many aspects (such as pluripotency and self-renewal), recognizing the signaling pathways through which ESCs maintain their stemness can also help identify CSC signaling. One component of these signaling pathways is microRNAs (miRNAs), and long non-coding RNAs (lncRNAs). miRNAs undergo altered expression in cancer. In this regard, they are classified as Onco-miRNAs or tumor suppressor miRNAs. Some miRNAs play similar roles in ESCs and CSCs, such as let-7 and miR-302. This review focuses on the miRNAs involved in stemness of ESCs and CSCs by presenting a summary of the role of miRNAs in other tumor cells.

Introduction

Cancer stem cells form a small population of cells that are very similar to stem cells within the tumor tissue. One theory is that tumors arise from a small population of cells called tumor-initiating cells (T-ICs) or cancer stem cells (CSCs). CSCs were first isolated from hematologic malignancies,1 and then from solid tumors and breast cancer.2 In 1961, it was found that there are cells in tumor tissue capable of producing a variety of tumors.3 There are three methods to isolate CSCs: i) isolation using flow cytometry based on Hoechst stain; ii) isolation based on surface marker expression; iii) sphere culture. Prominin-1 (CD133)4,5 and CD446,7 are two major cell surface markers used to isolate CSCs. These cells must have three properties: tumorigenicity, self-renewal and pluripotency.8,9 Classic treatments for cancer include chemotherapy, radiotherapy and antiangiogenic therapy against proliferating transit-amplifying cells. After a while, due to the presence of therapy-resistant cancer stem cells in tumor tissue, the cancer will appear again. Therefore, treatment should be performed simultaneously against these cells. For this purpose, the differentiation therapy strategy causes differentiation of these cells to proliferating transit-amplifying cells sensitive to classic treatments. This strategy, in which targeting of intracellular and extracellular signaling pathways causes disruption of stemness in CSCs, has proved to some extent to be successful.10,11

These cells undergo the same signaling pathways as embryonic stem cells (ESCs) such as Oct-4, Notch, Wnt, Sonic hedgehog (SHH) and Bmi-1.12,13 Most of these signaling pathways are involved in self-renewal of ESCs or tissue adult stem cells and cancer. Mutation and deregulated expression of some components of these signaling pathways has been shown in many human tumors, and hyperactivation of these pathways mostly contribute to tumor regeneration.14,15 Oct-4 is a core transcriptional regulatory circuitry in ESCs,16 and is necessary for reprogramming somatic cells into pluripotent state;17 it is also known as a pluripotency factor. Pluripotency helps CSCs to maintain an undifferentiated state, supporting the structure of tumor mass. Oct-4 and its partner Nanog have been shown to be expressed in many human tumors, and their downregulation causes a reduction in CSC stemness and resistance to chemotherapy.21,24

Contrary to mRNAs, as their name implies, non-coding RNAs (ncRNAs) do not encode for proteins. They are classified in two groups: those with less than 200 nucleotides (e.g. miRNAs), and those...
MicroRNAs and embryonic stem cells

Nearly 25% of the 110,000 known miRNAs are encoded by four clusters: miR-17-92 cluster, miR-21 loci, miR-290-295 cluster and miR-15b-16 cluster. The transcription factors Nanog/Oct4/Tcf3 bind the promoter of the miR-302, miR-290-371 cluster, miR-363 cluster, miR-148/152, miR-135b, miR-124, miR-615 and miR-708 clusters in the form of occupancy, and regulate their expression. Core transcriptional regulatory circuitry in ESCs includes Nanog/Oct4/Sox2, which along with Tcf3 causes the expression of Lin28, the latter subsequently inhibiting the processing of let-7. In this regulatory loop, let-7 has a negative effect on the expression of Lin28. Incoherent feed forward is one of the regulatory mechanisms of miRNAs in ESCs. In fact, we can say that miRNAs are the regulatory arm of transcription factors in expression regulation. Many studies have been performed on the effect of miRNAs in ESCs. MiR-145 inhibits pluripotency through inhibition of Oct-4, Sox2 and Klf4. In addition to being able to target 3'UTR in mRNA, miRNAs can target the coding sequence (CDS). MiR-200c inhibits the stemness property of CSCs, the reduced expression of which is observed in breast cancer. As it has previously been observed that p53 induces the differentiation of ESCs by binding to the regulatory region of Nanog gene, it is worth noting that the inhibition of stemness by p53 is also indirectly carried out by activating miRNAs such as miR-200 family members that inhibit BMI1, Sox2, Klf4 and Notch signaling. MiR-22 indirectly inhibits miR-200 expression and EMT induction in breast cancer by targeting TET and demethylation inhibition of miR-200 promoter. This study showed that miR-22 plays a role in epigenetic modification and enhances CSCs characteristics. In addition, it has been shown that miR-22 is up-regulated in myelodysplastic syndrome (MDS) and leukemia, and can be considered as a prognostic factor in these patients with low survival. MiR-22 targets Methyl cytosine dioxygenase TET2, developing hematopoietic stem cell self-renewal and maintaining stemness.

Another inducer of EMT is the miR-106b-25 cluster, which can promote EMT and CSCs characters in breast cancer model by targeting Smad7 (a negative regulator for TGF-β/BMP signaling pathway). MiR-203 can revert the EMT back to MET by targeting P57KIP2 as CDK inhibitor.

C-Myc is an important factor for reprogramming, especially in its early stages, controlling miRNAs expression by binding to their regulatory regions. It has been shown that C-Myc binds to miR-290-295, miR-141, miR-200 and miR-429 promoters. miRNAs profiles are changed during differentiation and reprogramming. Let-7 family, miR-210, miR-301, miR-136, miR-145, miR-29a/b, the miR-30 family and some other miRNAs are down-regulated during reprogramming, and some are up-regulated, such as miR-17-92, miR-106b-25 clusters, miR-183/194 and miR-302 cluster. Therefore, miRNAs promoting reprogramming and dedifferentiation can be proper candidates for knockdown and differentiation therapy studies. (For more details about the role of miRNAs in stemness and reprogramming, see52,62,76).

MicroRNAs and cancer stem cells

As mentioned above, reprogramming of differentiated cells into a dedifferentiation state is a stage in CSCs development. Therefore, some mechanisms that take place during reprogramming are involved in tumor development and CSCs formation. Fully differentiated cells undergo epithelial-mesenchymal transition (EMT) by losing adherent molecules (e.g. E-cadherin) and becoming migratory cells. Some factors involved in EMT, such as TGF-β, Notch1, Wnt, ZEB1/2 and Klf8 induce EMT by repressing E-cadherin expression. These cells are metastatic, and if they undergo mesenchymal-epithelial transition (MET), they can form CSCs. A number of miRNAs are involved in EMT as inducers or repressors (Table 2). The most well-known miRNA inhibitor of EMT is the miR-200 family. The miR-200 family and miR-205 inhibit TGF-β-induced EMT by targeting ZEB1 and SIP1, and downregulation of these miRNAs is required for induction of EMT in cancer cells. It is interesting that ZEB1 also blocks the expression of the miR-200 family and miR-141 by binding to their promoters. P53 is a repressor of EMT by binding to miR-200c promoter and activating its expression. It has been shown that miR-200c is down-regulated in breast cancer stem cells. By inhibiting klf4 transcription factor and polycomb repressor BMI1, miR-200c inhibits the stemness property of CSCs, the reduced expression of which is observed in breast cancer. As it has previously been observed that p53 induces the differentiation of ESCs by binding to the regulatory region of Nanog gene, it is worth noting that the inhibition of stemness by p53 is also indirectly carried out by activating miRNAs such as miR-200 family members that inhibit BMI1, Sox2, Klf4 and Notch signaling. MiR-22 indirectly inhibits miR-200 expression and EMT induction in breast cancer by targeting TET and demethylation inhibition of miR-200 promoter. This study showed that miR-22 plays a role in epigenetic modification and enhances CSCs characteristics. In addition, it has been shown that miR-22 is up-regulated in myelodysplastic syndrome (MDS) and leukemia, and can be considered as a prognostic factor in these patients with low survival. MiR-22 targets Methyl cytosine dioxygenase TET2, developing hematopoietic stem cell self-renewal and maintaining stemness.

Another inducer of EMT is the miR-106b-25 cluster, which can promote EMT and CSCs characters in breast cancer model by targeting Smad7 (a negative regulator for TGF-β/BMP signaling pathway). MiR-203 can revert the EMT back to MET by targeting P57KIP2, a predominant p53 isoform and oncogene which promotes CSCs proliferation in breast
cancer cells. Forced expression of miR-203 caused reduction in CD44+CD24− CSC population, and increased differentiation to luminal epithelial cells.\textsuperscript{55,56} (For more details about the role of miRNAs in EMT, see\textsuperscript{53,54}).

miR-34a, which is activated by p53,\textsuperscript{80} directly inhibits CD44 in prostate cancer stem cells; it causes inhibition of metastasis and prevents regeneration of cancer.\textsuperscript{81} In colon CSCs, tumor suppressor miR-34 targets Notch1 mRNA to disturb the balance between self-renewal and differentiation in Notch signaling. In this study, it was found that miR-34 determines cell fate in colon CSCs.\textsuperscript{82}

miR-9 and miR-9\textsuperscript{*} (miR-9/9\textsuperscript{*}) are expressed in CD133+ glioblastoma stem cells, and promote cell growth and maintain stemness by targeting Calmodulin-binding transcription activator 1 (CAMTA1), which is seen as a tumor suppressor.\textsuperscript{83} Inhibition of miR-9/9\textsuperscript{*} causes glioblastoma stem cell differentiation.\textsuperscript{84} It has been shown that miR-128 inhibits proliferation and self-renewal in glioma CSCs.\textsuperscript{85} miR-130b promotes stemness and tumorigenicity in CD133+ hepatocellular carcinoma (HCC) CSCs through inhibition of Tumor Protein P53 Inducible Nuclear Protein 1 (TP53INP1). Interestingly, forced expression of miR-130b in CD133+ cells assists in self-renewal activity and chemotherapy resistance.\textsuperscript{86}

As mentioned, miR-145 causes differentiation of ESCs by inhibiting the stemness factors.\textsuperscript{65} Interestingly, the expression of miR-145 in prostate and renal cancer cells is inhibited.\textsuperscript{67,88} In addition, miR-21 has been shown to induce stemness in colon cancer cells by modulating TGFβR2.\textsuperscript{89} Another miRNA down-regulated in CSCs is miR-140. This tumor suppressor miR reduces CSC self-renewal in breast CSCs by targeting Sox9 and ALDH1.\textsuperscript{90} Reduced expression of miR-30 has been shown in CSCs in breast cancer. Increased expression of miR-30 will reduce self-renewal and will increase apoptosis in these cells.\textsuperscript{91} miR-495, which up-regulates and targets E-cadherin, contributes to metastasis and DNA damage-inducible transcript 4 (DDIT4) to assist in proliferation and hypoxia resistance in breast CSCs.\textsuperscript{92} (For more details about the role of miRNAs in breast CSCs, see\textsuperscript{93}).

Altered expression of miR-142-3p, miR-451, miR-106a, miR-249 142-5p, miR-15b, miR-20a, miR-106b, miR-25, and miR-486 has been observed in lung cancer progenitor cells.\textsuperscript{94}

It has been shown that the expression of miR-302, specific for ES cells, causes the expression of stemness factors such as Nanog, Oct-4 and Sox2 in cancer cells, conferring a stem cell-like property to them, likely reprogramming these cells to CSCs.\textsuperscript{95} miR-328 helps in drug resistance and metastasis of colon CSCs by targeting ABCG2 and Matrix Metallopeptidase 16.\textsuperscript{96}

### Table 1. miRNAs involved in cancer.

| MicroRNAs | Cancer correlation | Function | References |
|-----------|--------------------|----------|------------|
| miR-15, miR-16 | Induce apoptosis and decrease tumorigenicity, suppress Bcl-2 | TS | 38,39 |
| miR-34a | Induce apoptosis, suppress E2F3, MYCN, CDK4 | TS | 40-42 |
| mir-143, mir-145 | Down-regulated in cancers | TS | 43 |
| mir-137, mir-193a | Suppress CDK6, E2F | TS | 44 |
| Let-7 | Induce apoptosis and differentiation. Suppress Ras, c-Myc and HMGA2 | TS | 45-47 |
| mir-21 | Anti-apoptosis, targets Bcl-2, TPM1, PDCD4 | OG | 48-51 |
| mir-155 | Up-regulated in lymphoma and breast cancer | OG | 52-54 |
| mir-27 | Targets ZBTB10, RYBP, MYT1 | OG | 55-56 |
| mir-17-19 cluster | Up-regulated in lymphomas and many types of cancers. Targets E2F1, Bin, Pten and Rb | TS/OG | 57-61 |

TS, tumor suppressor; OG, oncogene.

### Table 2. miRNAs involved in cancer stem cells.

| microRNA | Targets | Roles in cancer stem cells |
|----------|---------|----------------------------|
| miR-200 family | ZEB1 and SIP1, Bmi-1, Klf4 | Inhibition induction of EMT, inhibit BM1, Sox2, Klf4 and Notch signaling and reduce stemness in CSCs |
| Let-7 | Lin28, H-RAS and HMGA2 | Differentiation of CSCs |
| mir-302 | Genes involved in differentiation | Facilitate dedifferentiation of human tumor cells |
| mir-30 | ITGB3 and Ubc9 | Reduce self-renewal and increases apoptosis |
| mir-140 | Sox9 and ALDH1 | Reduce CSCs self-renewal |
| mir-145 | Oct-4, Sox2 and Klf4 | Inhibit stemness properties |
| miR-128 | Bmi-1 | Disrupting self-renewal of CSCs |
| Mir-34a | CD44 and Notch1 | Inhibition of self-renewal |
| mir-203 | ΔNP63α | Revert EMT to MET and reduction of CSCs population |
| mir-22 | TET | Indirectly repress miR-200 expression and enhance EMT and self-renewal |
| mir-106b-25 | Smad7 | Cause EMT and promote CSCs properties |
| mir-9/9\textsuperscript{*} | CAMTA1 | Maintain stemness property |
| mir-150b | TPS3PNP1 | Assist self-renewal activity and chemotherapy resistance |
| mir-21 | TGFβR2 | Enhance stemness properties |
| mir-495 | E-cadherin and DDIT4 | Promote metastasis, proliferation and hypoxia resistance of CSCs |
| mir-328 | ABCG2 and MMP16 | Assist metastasis and drug resistance |

CSCs, cancer stem cells; EMT, epithelial-mesenchymal transition; MET, mesenchymal-epithelial transition.
Finally, the reduced expression of let-7 has been demonstrated in many cancers.\textsuperscript{97–99} Let-7 inhibits H-RAS and HMGA2.\textsuperscript{100} This factor is controlled by Lin-28; however, methylation of its gene has been observed in lung cancer.\textsuperscript{101} Differentiation of ES cells increases its level; therefore, its expression is expected to decrease in CSCs. As expected, let-7 is significantly decreased in breast CSCs.\textsuperscript{102}

**Discussion**

Recognizing CSCs as factors of resistance to chemotherapy and recurrence of tumor tissue requires identification of the mechanisms that regulate these cells for therapeutic targets. Since these cells show signaling similar to ESCs and have the two main features of stemness, including pluripotency and self-renewal, they appear to have similarities in expression of stemness factors. Thus, for differentiation therapy purposes, intra- and extracellular mechanisms that maintain this stemness should be further identified. Understanding transcriptome of pluripotency would help find more targets in differentiation therapy of cancer.

Since no specific research has been conducted to identify the miRNAs in various types of CSCs to identify miRNA profiling, we can resort to identifying the miRNAs of ESCs, which are very similar to CSCs. In addition, it has been shown that many of the miRNAs act in nucleus in upregulation of genes by binding to the promoters or antisense transcripts.\textsuperscript{103} Therefore, it would be interesting if such miRNAs that cause upregulation of tumor suppressor genes or differentiation in CSCs can be found. An interesting study using RNAseq technique showed that most of the miRNAs are transported to nucleus after maturation in cytoplasm.\textsuperscript{104} The interesting point is that miRNAs that are important in maintaining stemness and differentiation induction in ESCs like mir-145, miR-302 and let-7 play similar roles in CSCs. Further studies are required to better understand the role of miRNAs in CSCs. Focusing on this topic can help find new drugs and more effective treatments for cancer. Finally, in line with basic research for finding new targets for treatment, attempts at specific delivery of miRNAs into tumor cells, especially CSCs, should also be approved. Use of active delivery instead of passive delivery by using targeted nanoparticles showed more specificity in drug delivery, and phase II/II clinical trials are ongoing.\textsuperscript{105} (For more details about nanoparticle drug delivery, see \textsuperscript{106}).

**References**

1. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.

2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-8.

3. Southam CM, Brunschwig A. Quantitative studies of autotransplantation of human cancer. Preliminary report. Cancer 2006;14:971-8.

4. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.

5. O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.

6. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104:10158-63.

7. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708.

8. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005;15:494-501.

9. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-44.

10. Sell S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev 2005;1:197-205.

11. Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004;51:1-28.

12. Tai MH, Chang CC, Kiupel M, et al. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis 2005;26:495-502.

13. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:679-99.

14. Don tu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:R605-15.

15. Farnie G, Clarke RB. Mammary stem cells and breast cancer-role of Notch signalling. Stem Cell Rev 2007;3:169-75.

16. Jones DL, Wagers AJ. No place like home: anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol 2008;9:11-21.

17. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-98.

18. Liu S, Don tu G, Mantle ID, et al. Hedgehog signalling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-71.

19. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-56.

20. Buganim Y, Faddah DA, Jaenisch R. Mechanisms and models of somatic cell reprogramming. Nat Rev Genet 2013;14:427-39.

21. Noh KH, Kim BW, Song KH, et al. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest 2012;122:4077-93.

22. Nagata S, Hirano K, Kanemori M, et al. Self-renewal and pluripotency acquired through somatic reprogramming to human cancer stem cells. PLoS One 2012;7:e48699.

23. Kang J, Shakya A, Tantin D. Stem cells, stress, metabolism and cancer: a drama in two Octs. Trends Biochem Sci 2009;34:491-9.

24. Ibrahim EE, Babae-Jadidi R, Saadeddin A, et al. Embryonic NANOG activity defines colorectal cancer stem cells and modulates through AP1- and TCF-dependent mechanisms. Stem Cells 2012;30:2076-87.

25. Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 2010;142:409-19.

26. Tsai MC, Spittle RC, Chang HY. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 2011;71:3-7.

27. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet 2010;19:R52-61.

28. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011;10:38.

29. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54.

30. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 2007;8:23-36.

31. Rossi JJ. Transcriptional activation by small RNA duplexes. Nat Rev Genet 2013;14:427-39.

32. Huang V, Place RF, Portnoy V, et al. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res 2012;40:645-54.
33. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.

34. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.

35. O'Donnell KA, Wentzel EA, Zeller KL, et al. E-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43.

36. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.

37. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005;33:5394-403.

38. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9.

39. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Oncogene 2005;24:3986-97.

40. Wei JS, Song YK, Durink S, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008;27:5204-13.

41. Welch C, Chen Y, Stalling RS. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007;26:5017-22.

42. Raver-Shapira N, Marciano E, Meiri E, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Molecular Cell 2007;26:731-43.

43. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.

44. Kozaki K, Imoto I, Mogi S, et al. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68:2094-105.

45. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2002;109:1394-9.

46. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMG2A oncogene. Genes Dev 2007;21:1025-30.

47. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cancer cells. Cancer Res 2007;67:9762-70.

48. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008;9:582-9.

49. Chang CJ, Chao CH, Xia W, et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011;13:317-23.

50. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138:592-603.

51. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009;11:1487-95.

52. Greve TS, Judson RL, Blei Rocher L. miRNA Control of Mouse and Human Pluripotent Stem Cell Behavior. Annu Rev Cell Dev Biol 2013;29:213-39.

53. Xia H, Hui KM. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cell properties as molecular targets for cancer therapeutics. Cancer Gene Ther 2012;19:723-30.

54. Ceppi P, Peter ME. MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene. 2013, [Epub ahead of print].

55. Keyes WM, Pecoraro M, Aranda V, et al. DeltaNp63Alphalpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2011;8:164-76.

56. DeCastro AJ, Dunphy KA, Hutchison J, et al. MiR203 mediates subversion of stem cell properties during mammary epithelial differentiation via repression of DeltaNP63Alphalpha and promotes mesenchymal-to-epithelial transition. Cell Death Dis 2013;4:e514.

57. Lin T, Chao C, Saito S, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005;7:165-71.

58. Vallejo DM, Caparros E, Dominguez M. Targeting Notch signalling by the conserved miR-8200 microRNA family in development and cancer cells. EMBO J 2011;30:756-68.

59. Song SJ, Poliseno L, Song MS, et al. MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. Cell 2013;154:311-24.

60. Song SJ, Ito K, Ala U, et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013;13:87-101.

61. Smith AL, Iwanaga R, Drasin DJ, et al. The miR-106b-25 cluster targets Snad1, activates TGF-beta signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 2012;31:5162-71.

62. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009;10:116-25.

63. Houhavy HB, Murray MF, Sharp PA. Embryonic stem cell-specific MicroRNAs. Dev Cell 2003;5:351-8.

64. Marson A, Levine SS, Cole MF, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008;134:521-33.

65. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blei Rocher R. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Nat Genet 2008;40:1478-83.

66. Pekarsky Y, Santanam U, Cimmino A, et al. Tcf11 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66:11590-3.

67. Tay Y, Zhang J, Thomson AM, et al. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008;455:1124-8.

68. Vierbuchen T, Wernig M. Molecular roadblocks for cellular reprogramming. Mol Cell 2012;47:927-38.

69. Subramanyam D, Lamouille S, Judson RL, et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 2011;29:443-8.

70. Sengupta S, Nie J, Wagner RJ, et al. MicroRNA 92b controls the G1/S checkpoint gene p57 in human embryonic stem cells. Stem Cells 2009;27:1524-8.

71. Polo JM, Anderssen E, Walsh RM, et al. A molecular roadmap of reprogramming somatic cells into iPSC cells. Cell 2012;151:1617-32.

72. Judson RL, Babiarz JE, Venere M, Blei Rocher R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 2009;27:459-61.

73. Lin CH, Jackson AL, Guo J, et al. Msc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J 2009;28:3157-70.

74. Chen J, Wang G, Lu C, et al. Synergetic cooperation of microRNAs with transcription factors in iPSC cell generation. PLoS One 2012;7:e40849.

75. Wang T, Chen K, Zeng X, et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell 2011;9:575-87.

76. Sartipy P, Olsson B, Hyllner J, Syngenren J. Regulation of stemness and stem cell differentiation by microRNAs. I Drugs 2009;12:492-6.
| Page 58 | Oncology Reviews 2013; 7:e8 |
|---|---|
| 91. Yu F, Deng H, Yao H, et al. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010;29:4194-204. |
| 92. Hwang-Verslues WW, Chang PH, Wei PC, et al. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011;30:2463-74. |
| 93. Schwarzenbacher D, Balic M, Pichler M. The Role of MicroRNAs in Breast Cancer Stem Cells. Int J Mol Sci 2013;14:14712-23. |
| 94. Qian S, Ding JY, Xie R, et al. MicroRNA expression profile of bronchioalveolar stem cells from mouse lung. Biochem Biophys Res Commun 2008;377:668-73. |
| 95. Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008;14:2115-24. |
| 96. Xu XT, Xu Q, Tong JL, et al. MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer 2012;106:1320-30. |
| 97. Michael MZ, SM OC, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-91. |
| 98. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6. |
| 99. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26:4442-52. |
| 100. Park SM, Shell S, Radjabi AR, et al. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGAl. Cell Cycle 2007;6:2585-90. |
| 101. Brueckner B, Stresemann C, Kuner R, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007;67:1419-23. |
| 102. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23. |
| 103. Portnoy V, Huang V, Place RF, Li IC. Small RNA and transcriptional upregulation. Wiley Interdiscip Rev RNA 2011;2:748-60. |
| 104. Liao JY, Ma LM, Guo YH, et al. Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3’ trailers. PLoS One 2010;5:e10563. |
| 105. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82. |
| 106. Huang L, Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 2011;13:507-30. |